Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Clinical trial NCT05422027 · UNKNOWN

Trial details

NCT number: NCT05422027
Sponsor: Xia Zhongjun
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2022-07-25
Primary completion: 2025-06-30
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.